CEBP Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cicek, M. S.
Right arrow Articles by Witte, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cicek, M. S.
Right arrow Articles by Witte, J. S.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 2173-2177, September 2005
© 2005 American Association for Cancer Research

Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11{alpha} in Prostate Cancer Risk and Aggressiveness

Mine S. Cicek1, Xin Liu2, Graham Casey1 and John S. Witte2

1 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio and 2 Department of Epidemiology and Biostatistics, University of California, San Francisco, California

Requests for reprints: John S. Witte, Department of Epidemiology and Biostatistics, University of California, San Francisco, 500 Parnassus Avenue, MU-420 West San Francisco, CA 94143-0560. Phone: 415-476-1374; Fax: 415-476-6014. E-mail: jwitte{at}itsa.ucsf.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
Candidate genes involved with androgen metabolism have been hypothesized to affect the risk of prostate cancer. To further investigate this, we evaluated the relationship between prostate cancer and multiple potentially functional polymorphisms in three genes involved in androgen metabolism: CYP1B1 (two single nucleotide polymorphisms: 355G/T and 4326C/G), prostate-specific antigen (PSA/KLK3 (three single nucleotide polymorphisms: –158A/G, –4643G/A, and –5412C/T), and CYP11{alpha} [(tttta)n repeat], using a moderately large (n = 918) sibling-based case-control population. When looking at all subjects combined, no association was observed between any polymorphism—or their haplotypes—and prostate cancer risk. However, among men with more aggressive prostate cancer, the CYP1B1 355G/T variant was positively associated with disease: carrying one or two T alleles gave odds ratios (OR) of 1.90 [95% confidence interval (95% CI), 1.09-3.31; P = 0.02] and 3.73 (95% CI, 1.39-10.0; P = 0.009), respectively. Similarly, carrying the CYP1B1 355T-4326C haplotype was positively associated with prostate cancer among men with high aggressive disease (P = 0.01). In addition, the PSA –158G/–158G genotype was positively associated with prostate cancer among men with less aggressive disease (OR, 2.71; 95% CI, 1.06-6.94; P = 0.04). Our findings suggest that CYP1B1 and PSA variants may affect the risk of prostate cancer and tumor aggressiveness.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
The causes of prostate cancer are not well known, but both genetic and environmental influences likely play a role. The prostate is an androgen-dependent organ and polymorphic variants in a number of genes involved in androgen metabolism have been implicated in prostate cancer risk. For example, we previously reported that SRD5A2, CYP3A4, and CYP3A5 variants may influence risk of developing prostate cancer or more aggressive disease (1, 2). Additional studies have suggested that variants in other genes involved in androgen metabolism or response, such as CYP1B1, prostate-specific antigen (PSA/KLK3), and CYP11{alpha}, may also play a role in prostate cancer risk.

CYP1B1 maps to chromosomal region 2p21-22 (3) and is involved in the activation of many procarcinogens and the hydroxylation of testosterone. Several polymorphisms in the CYP1B1 gene have been described (4), including two common single nucleotide polymorphisms (SNP): 355G/T (A119S) in exon 2, which is located in the substrate recognition site one (SR1S), and 4326C/G (L432V) in exon 3, which encodes the heme-binding domain. Functional studies suggest that these nonsynonymous SNPs may alter enzymatic activity and catalytic specificity of CYP1B1 (5). Several studies have evaluated the relationship between these CYP1B1 polymorphisms and risk of various cancers. These include colorectal (6), breast (7-11), ovarian (12), and prostate cancers (13-15). With regard to the latter, carrying the CYP1B1 355T allele, or the 4326G/G genotype, has been positively associated with prostate cancer among Japanese (14) and Caucasians (13), respectively. A more recent report, however, found an inverse association between a haplotype including 355T-4326C and sporadic prostate cancer (15).

The gene encoding PSA is regulated by the androgen receptor, which binds to androgen-responsive elements. Serum PSA level is used to screen for prostate cancer because it is often elevated in prostate cancer patients. PSA (also known as KLK3) is located on human chromosome 19q13.3-13.4, a region previously linked to advanced prostate cancer (16, 17). Both PSA/KLK3 –158A/G promoter variant alleles (i.e., –158A and –158G) have been associated with prostate cancer risk (18, 19). In addition, this variant has been positively associated with higher PSA levels in some studies, although other studies have found inverse or null associations (19-23). The –158A/G variant may be in linkage disequilibrium with the potential causal variants: a recent study of men without prostate cancer found that two other promoter polymorphisms, –4643G/A and –5412C/T (but not –158A/G), are associated with serum PSA levels and PSA promoter activity (22).

The CYP11{alpha} gene encodes the cholesterol P450 side-chain cleavage enzyme that catalyzes the conversion of cholesterol to pregnenolone mediating the first rate-limiting step in testosterone synthesis (24). CYP11{alpha} is located on chromosome 15q23-24 and the promoter region of this gene is believed to contain multiple cyclic AMP–regulated elements that are responsible for increasing basal transcriptional activity (25). Up-regulation of this enzyme may lead to an increase in androgen production (26). A microsatellite polymorphism (tttta)n was identified in the promoter region of CYP11{alpha}, located 528 bp upstream from the initiation site of the translation of the gene (26). Recent studies have shown this polymorphism to be associated with increased risk of advanced prostate cancer (27), polycystic ovary syndrome (26, 28), and breast cancer (29).

In light of these existing results, here we aimed to further clarify the relation of polymorphisms in CYP1B1, PSA/KLK3, and CYP11{alpha} with prostate cancer and tumor aggressiveness using a sibling-based case-control population.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Study Subjects
The study design and population have been described elsewhere (1). Briefly, siblings (n = 918; 439 cases and 479 controls from 413 families) were recruited from the major medical institutions in the greater Cleveland, Ohio area and from the Henry Ford Health System, Detroit, Michigan. Ninety-one percent of the subjects were Caucasian, 8% were African American, and 1% were Asian or Latino. Institutional Review Board approval was obtained from the participating institutions and all study participants gave informed consent.

Sibling sets consisted of men with prostate cancer diagnosed at age 73 or younger and at least one brother without prostate cancer. The case clinical characteristics at diagnosis (e.g., Gleason score, tumor stage) were obtained from medical records and their disease status was confirmed histologically. All controls were no more than 8 years younger than their brother's age at diagnosis. The disease status of unaffected brothers was further confirmed through testing of PSA levels whenever possible (93% of controls). If a control's PSA level was elevated (>4 ng/mL), they were referred for further evaluation by our collaborating urologists. We followed up these individuals to confirm that they remained disease-free. These criteria were selected in an attempt to minimize potential for misclassification of prostate cancer status amongst controls (30, 31). We chose to use this sibling-based study design to ensure that our control group was selected from the same genetic source population as the cases, and is thus not subject to population stratification from factors such as race (32).

Genotype Analysis
Standard venipuncture was used to collect blood samples from all study participants in tubes with EDTA as an anticoagulant. Genomic DNA was extracted from buffy coats using the QIAmp DNA Blood kit (QIAGEN, Inc., Valencia, CA). All purified DNA samples were diluted to a constant DNA concentration of 5 ng/µL in 10 mmol/L Tris, 5 mmol/L EDTA buffer (pH 8).

CYP1B1. The CYP1B1_L432V polymorphism (+4326C/G; rs1056836) was detected by amplifying genomic DNA. PCR products were digested with restriction enzyme and the digested products were separated on an agarose gel. Analysis of CYP1B1_A119S (+355G/T; rs1056827) variant was done using the Amplifluor Uniprime SNP Detection System (Chemicon Intl., Serological Corp., Norcross, GA). The method included a "hot start" two-step PCR reaction followed by allelic discrimination protocol using the ABI Prism 7900HT (Applied Biosystems, Foster City, CA) for an end-point read and analysis.

PSA/KLK3. The PSA/KLK3 G–158A (rs266882), A–4643G (rs925013), and T–5412C (rs2739448) polymorphisms were detected by amplifying genomic DNA. PCR products were digested with restriction enzyme and the digested products were separated on an agarose gel.

CYP11{alpha}. The CYP11a (tttta)n microsatellite polymorphism was detected by amplifying genomic DNA. The forward primer was fluorescently labeled by Beckman color green (D3). PCR product fragment lengths were analyzed on a CEQ 8000 genetic analysis system (Beckman Coulter, Fullerton, CA). The number of (tttta) repeats was confirmed by sequencing at least one sample of each PCR product length that we observed.

To ensure quality control of genotyping results, 5% of samples were randomly selected and genotyped by a second investigator and 1% was sequenced using a 377 ABI automated sequencer (all results were concordant).

Statistical Analysis
A {chi}2 goodness of fit test was used to assess deviation from Hardy-Weinberg equilibrium for genotype frequencies of each variant. For the three SNPs in PSA/KLK3 and two SNPs in CYP1B1, linkage disequilibrium was calculated using HAPLOVIEW (http://www.broad.mit.edu/personal/jcbarret/haploview/index.php) in Caucasian or African American controls (randomly selecting one control from each family). Next, we reconstructed diplotypes (i.e., joint haplotypes) for both PSA and CYP1B1 with the program PHASE (33), initially ignoring relations among siblings. We then estimated diplotypes incorporating relations for families with >2 siblings in the study, using MERLIN (MERLIN v1.0-{alpha}, http://www.sph.umich.edu/csg/abecasis/Merlin). The assigned diplotypes were identical using these two approaches.

Conditional logistic regression (using family as the matching variable, and a robust variance estimator that incorporates familial correlations) was used to estimate odds ratios (OR) and corresponding 95% confidence intervals (95% CI) for the relation between genotypes/diplotypes and prostate cancer. The rare diplotypes (observed in <4% of the entire sample) were collapsed into one group. We also did analyses by grouping diplotypes according to the number of haplotype of interest. The regression model was adjusted for potential confounding by age. To investigate the potential effect of genotypes/diplotypes on disease aggressiveness, we stratified the analyses by the cases clinical characteristics at diagnosis (n = 860). A total of 58 individuals (cases and controls) did not have a complete clinical data and, therefore, were not included in the analyses stratified by disease aggressiveness. Following Rebbeck et al. (34), aggressiveness was defined as "low" if the Gleason score of a case was <7 and the tumor category was <T2C, and "high" if the Gleason score was ≥7 or the tumor category was ≥T2C. The tumor category reflects the tumor-node-metastasis system. All P values are from two-sided tests, and all analyses were undertaken with SAS software (version 8.2, SAS Institute, Cary, NC).


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
The present study evaluated the potential association between prostate cancer and polymorphisms in three genes involved in androgen metabolism: CYP1B1, PSA/KLK3, and CYP11{alpha}. The mean ages of cases and controls were 61 and 63 years, respectively, as expected based on our recruitment of slightly older controls. Also as expected, cases had much higher PSA levels in comparison with the controls (mean PSA: 14.8 versus 2.2). About half of our cases were diagnosed with more advanced prostate cancer: 191 (45%) had Gleason scores ≥7, and 55 (13%) have tumor stage ≥T2C (Supplementary Table S1). The variants in PSA and CYP1B1 were in Hardy-Weinberg equilibrium and had strong linkage disequilibrium within genes (D' > 0.8).

Table 1 provides ORs for the association between variants in CYP1B1 and prostate cancer. Among all study subjects, there was no association between the two variants (G355T and C4326G) and prostate cancer, although there was a weak positive association for the T-C/T-C diplotypes (OR, 2.17; 95% CI, 1.01-4.67; P = 0.05). This result was strengthened among men with more aggressive disease: in comparison with men homozygous for the G-G haplotype (i.e., for SNPs G355 and 4326G), men carrying the T-C haplotype had statistically significantly increased risk, except for the diplotype G-C/T-C (Table 2). When we grouped diplotypes according to the number of T-C haplotypes, carrying one and two copies of this haplotype was associated with aggressive prostate cancer, with ORs of 1.99 (95% CI, 1.15-3.47; P = 0.01) and 4.00 (95% CI, 1.36-11.8; P = 0.01). This effect seemed to be primarily due to the G355T SNP. Specifically, in comparison with the GG genotype, carrying one or two T alleles gave ORs for prostate cancer of 1.90 (95% CI, 1.09-3.31; P = 0.02) and 3.73 (95% CI, 1.30-10.0; P = 0.009), respectively (P for trend = 0.004). This finding is in agreement with studies of prostate (14) and breast and lung cancers (35). Other studies, however, reported an inverse association between prostate cancer and a haplotype including 355T-4326C (15), and a positive association with the C4326G SNP alone (13). These conflicting results might be explained by the very small sample size included in the latter study (n = 50) and our observation that not all haplotypes carrying the 355T allele led to an increased risk. Whereas functional studies support the direct role of these variants on disease risk (5), there may be a causal variant residing on or near the corresponding haplotype. No noteworthy associations were observed among men with low aggressive prostate cancer (Table 2).


View this table:
[in this window]
[in a new window]
  		Table 1. Association between CYP1B1 variants and prostate cancer in the entire family-based study sample, stratified by disease aggressiveness

 

View this table:
[in this window]
[in a new window]
  		Table 2. Relation between variants in PSA/KLK3 and prostate cancer in the entire family-based study sample, stratified by disease aggressiveness

 
When looking at KLK3/PSA, no associations were observed for the three SNPs (A–158G, A–4653G, and T–5412C), or their haplotypes, among the entire sample (Table 3). However, we observed a statistically significant association between the A–158G variant and prostate cancer among men with nonaggressive disease. In comparison with men homozygous for the –158A allele, carrying the GG genotype gave an OR of 2.71 (95% CI, 1.06-6.94; P = 0.04). And there was a slight trend across genotypes, as each additional copy of the 158G variant seemed to increase the respective ORs (P for trend = 0.03). Similar, albeit weaker, results were observed for the PSA haplotypes: men with diplotypes carrying two copies of the –158G variant exhibited increased risk of disease (though not statistically significant; Table 2). In contrast, within the higher aggressiveness stratum, all nonreferent diplotypes (i.e., not AAT/AAT) were weakly inversely associated with disease (P ≥ 0.04). Analyses for the number of GGC haplotypes did not materially change the above results (Table 3). This is in general agreement with two previous studies (18, 36); however, another study observed a positive association between carrying two copies of the –158A variant and disease (19). Of course, the –158A/G SNP may be in linkage disequilibrium with the causal variants in the PSA/KLK3 promoter region. However, we found no associations for two other promoter polymorphisms (G–4643G and C–5412T). In addition, three-locus (A–158G, G–4643A, and C–5412T) haplotype analyses did not improve the results observed for the single A–158G variant. To this end, functional studies suggest that the proliferation, migration, and metastasis of prostate cancer cells may be due to the enzymatic activity of PSA/KLK3 (37). Our findings suggest that the –158G/–158G may be involved in disease risk via this enzymatic pathway reflecting the effect of other functional variants.


View this table:
[in this window]
[in a new window]
  		Table 3. Association between CYP11{alpha} variants and prostate cancer, in the entire family-based study sample, stratified by disease aggressiveness

 
Finally, we observed no associations between the CYP11{alpha} (tttta) repeat and prostate cancer risk or tumor aggressiveness (Table 3). Here we recoded genotypes for CYP11{alpha} as three groups: noncarriers of 4 (tttta) repeat allele (none), subjects carrying one 4 (tttta) repeat allele (one copy), and homozygotes for 4 (tttta) repeat alleles (two copies). Using other codings for the genotypes did not alter our null results (not shown). Our observation of no overall association between prostate cancer and the CYP11A (tttta)n variant is consistent with a previous study (27). Nevertheless, Kumazawa et al. (27) did observe that the absence of the (tttta)n variant was associated with an increased risk of stage D disease (i.e., T1-4N1M0-1 or T1-4N0-1M1 according to the Whitmore-Jewett system; ref. 38). Our inability to replicate their results may in part reflect the small number of men in our study with such high-stage prostate cancer.

By using a family-based design, the current study is not susceptible to confounding bias due to population stratification (39). Nevertheless, studying brothers with and without prostate cancer can lead to overmatching and subsequent reduced power for detecting genetic effects (32).

In summary, we found evidence that polymorphisms in CYP1 and PSA/KLK3 may affect the risk of prostate cancer among men with more and less advanced disease, respectively. Moreover, these genes may contain other functional variants that affect the aggressiveness of prostate cancer.


   Footnotes
 
Grant support: NIH grants CA88164 and CA94211.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: M.S. Cicek and X. Liu contributed equally to this work.

Supplementary data for this article are available at Cancer Epidemiology Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

Received 3/26/05; revised 6/ 7/05; accepted 6/22/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:928–32.[Abstract/Free Full Text]
  2. Cicek MS, Conti DV, Curran A, et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004;59:69–76.[CrossRef][Medline]
  3. Sutter CH, Qian Z, Hong YP, Mammen JS, Strickland PT, Sutter TR. Genotyping human cytochrome: P450 1B1 variants. Methods Enzymol 2002;357:53–8.[Medline]
  4. Stoilov I, Akarsu AN, Alozie I, et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998;62:573–84.[CrossRef][Medline]
  5. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61:586–94.[Abstract/Free Full Text]
  6. Fritsche E, Bruning T, Jonkmanns C, Ko Y, Bolt HM, Abel J. Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma. Pharmacogenetics 1999;9:405–8.[Medline]
  7. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998;58:5038–41.[Abstract/Free Full Text]
  8. Coughlin SS, Piper M. Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:1023–32.[Free Full Text]
  9. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843–54.[Abstract/Free Full Text]
  10. Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000;462:323–33.[CrossRef][Medline]
  11. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:489–92.[Abstract/Free Full Text]
  12. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209–16.[Abstract/Free Full Text]
  13. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761–6.[CrossRef][Medline]
  14. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 2002;296:820–6.[CrossRef][Medline]
  15. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003;89:1524–9.[CrossRef][Medline]
  16. Slager SL, Schaid DJ, Cunningham JM, et al. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet 2003;72:759–62.[CrossRef][Medline]
  17. Witte JS, Suarez BK, Thiel B, et al. Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate 2003;57:298–308.[CrossRef][Medline]
  18. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000;60:839–41.[Abstract/Free Full Text]
  19. Medeiros R, Morais A, Vasconcelos A, et al. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 2002;53:88–94.[CrossRef][Medline]
  20. Xue WM, Coetzee GA, Ross RK, et al. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2001;10:575–9.[Abstract/Free Full Text]
  21. Xu J, Meyers DA, Sterling DA, et al. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 2002;11:664–9.[Abstract/Free Full Text]
  22. Cramer SD, Chang BL, Rao A, et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 2003;95:1044–53.[Abstract/Free Full Text]
  23. Rao A, Chang BL, Hawkins G, et al. Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 2003;61:864–9.[CrossRef][Medline]
  24. Durocher F, Morissette J, Simard J. Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. Pharmacogenetics 1998;8:49–53.[CrossRef][Medline]
  25. Sparkes RS, Klisak I, Miller WL. Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25. DNA Cell Biol 1991;10:359–65.[Medline]
  26. Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397–402.[Abstract/Free Full Text]
  27. Kumazawa T, Tsuchiya N, Wang L, et al. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer 2004;110:140–4.[CrossRef][Medline]
  28. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta)(n) at –528 base pairs of gene CYP11{alpha} influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000;73:735–41.[CrossRef][Medline]
  29. Zheng W, Gao YT, Shu XO, et al. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:709–14.[Abstract/Free Full Text]
  30. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63–75.[CrossRef][Medline]
  31. Poole C. Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. Am J Epidemiol 1999;150:547–51.[Abstract/Free Full Text]
  32. Witte JS, Gauderman WJ, Thomas DC. Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. Am J Epidemiol 1999;149:693–705.[Abstract/Free Full Text]
  33. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–89.[CrossRef][Medline]
  34. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225–9.[Abstract/Free Full Text]
  35. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000;10:25–33.[CrossRef][Medline]
  36. Chiang CH, Chen KK, Chang LS, Hong CJ. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J Urol 2004;171:1529–32.[CrossRef][Medline]
  37. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275–368.[CrossRef][Medline]
  38. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 1994;74:104–14.[CrossRef][Medline]
  39. Thomas DC, Witte JS. Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev 2002;11:505–12.[Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
B. A. Rybicki, C. Neslund-Dudas, C. H. Bock, A. Rundle, A. T. Savera, J. J. Yang, N. L. Nock, and D. Tang
Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate and Biochemical Recurrence after Prostatectomy
Clin. Cancer Res., February 1, 2008; 14(3): 750 - 757.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Cussenot, A. R. Azzouzi, N. Nicolaiew, G. Fromont, P. Mangin, L. Cormier, G. Fournier, A. Valeri, S. Larre, F. Thibault, et al.
Combination of Polymorphisms From Genes Related to Estrogen Metabolism and Risk of Prostate Cancers: The Hidden Face of Estrogens
J. Clin. Oncol., August 20, 2007; 25(24): 3596 - 3602.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. L. Nock, D. Tang, A. Rundle, C. Neslund-Dudas, A. T. Savera, C. H. Bock, K. G. Monaghan, A. Koprowski, N. Mitrache, J. J. Yang, et al.
Associations between Smoking, Polymorphisms in Polycyclic Aromatic Hydrocarbon (PAH) Metabolism and Conjugation Genes and PAH-DNA Adducts in Prostate Tumors Differ by Race
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1236 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Lai, M.-A. Kedda, K. Hinze, R. L.G. Smith, J. Yaxley, A. B. Spurdle, C.P. Morris, J. Harris, and J. A. Clements
PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility
Carcinogenesis, May 1, 2007; 28(5): 1032 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. L. Nock, M. S. Cicek, L. Li, X. Liu, B. A. Rybicki, A. Moreira, S. J. Plummer, G. Casey, and J. S. Witte
Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk
Carcinogenesis, September 1, 2006; 27(9): 1842 - 1848.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. L. Nock, X. Liu, M. S. Cicek, L. Li, F. Macarie, B. A. Rybicki, S. J. Plummer, G. T. MacLennan, G. Casey, and J. S. Witte
Polymorphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and prostate cancer risk.
Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 756 - 761.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cicek, M. S.
Right arrow Articles by Witte, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cicek, M. S.
Right arrow Articles by Witte, J. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation